EFFECTIVENESS OF TENOFOVIR/EMTRICITABINE VERSUS ZIDOVUDINE/LAMIVUDINE IN COMBINATION WITH EFAVIRENzung IN ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS

SITI MAHANIM BINTI SHAIK ISMAIL

Dissertation submitted in partial fulfilment of the requirements for the degree of Master in Clinical Pharmacy

Faculty of Pharmacy

January 2015
CONFIRMATION BY PANEL OF EXAMINERS

I certify that a panel of examiners has met on 15th January 2015 to conduct the final examination of Siti Mahanim bt Shaik Ismail on her Master of Clinical Pharmacy dissertation entitled “Effectiveness Of Tenofovir/Emtricitabine Versus Zidovudine/Lamivudine in Combination with Efavirenz in Antiretroviral-Naïve HIV-Infected Patients” in accordance with Universiti Teknologi MARA Act 1976 (Akta 173). The Panel of Examiners recommends that the student be awarded the relevant degree. The Panel of Examiners was as follows:

Noorizan Abd Aziz, PhD
Professor
Faculty of Pharmacy
Universiti Teknologi MARA
(Chairman)

Yogeshwaran Gopalan, PhD
Faculty of Pharmacy
Universiti Teknologi MARA
(Internal Examiner)

Shariza Sahudin, PhD
Faculty of Pharmacy
Universiti Teknologi MARA
(External Examiner)

..............................................
Aishah Adam, PhD
Professor
Dean
Faculty of Pharmacy
Universiti Teknologi MARA
Date: 23rd February, 2015
AUTHOR'S DECLARATION

I declare that the work in this dissertation was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the result of my own work, unless otherwise indicated or acknowledge as referenced work. This thesis has not been submitted to any other academic institution or non-academic institution for any degree or qualification.

I, hereby, acknowledge that I have been supplied with Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name of Student : Siti Mahanim bt Shaik Ismail
Student I.D. No. : 2013458982
Programme : Master of Clinical Pharmacy
Faculty : Pharmacy
Dissertation : Effectiveness Of Tenofovir/Emtricitabine Versus Zidovudine/Lamivudine in Combination with Efavirenz in Antiretroviral-Naïve HIV-Infected Patients

Signature of Student : ..............................................................
Date : January 2015
ABSTRACT

Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere. Combination of two NRTIs and one NNRTI is the best first line regimen in treating retroviral disease (RVD) as compared to combinations of other groups. Tenofovir and Zidovudine are the two drugs that mostly use as one of NNRTIs in combination with either Lamivudine or Emtricitabine. Review of previous literature had shown that there were conflicting data on the superiority of either regime based on virologic and immunologic response. A local, retrospective observational cohort study was conducted to evaluate the virological response (primary endpoint), immunological response and the safety profile between TDF and AZT regimens. A total of 154 ART-naïve samples from HTAR and HSB were recruited. No statistically significant differences were observed in HIV RNA suppression at 24 weeks and 48 weeks (p = 0.407 and p = 0.521, respectively). Mean difference in CD4 increments were also not significant (p = 0.54, 95% CI -59.97, 31.83 at week 24; p = 0.68, 95% CI -51.41, 33.59 at week 48). However, AZT was found with more adverse events that leads to discontinuation (p-value <0.001). There were two cases of virological failure in TDF group but the association was not significant (p = 0.497). Only education level was identified as predictor of therapy effectiveness. Although there was no significant difference in virological and immunological responses, TDF still has advantage over AZT because of its better safety profile.
# TABLE OF CONTENTS

CONFIRMATION BY PANEL OF EXAMINERS .................................................. ii

AUTHOR'S DECLARATION .............................................................................. iii

ABSTRACT .................................................................................................... iv

ACKNOWLEDGEMENT ................................................................................... v

TABLE OF CONTENTS .................................................................................. vi

LIST OF TABLES ........................................................................................... ix

LIST OF FIGURES ........................................................................................ xi

LIST OF SYMBOL, ABBREVIATION AND NOMENCLATURE ....................... xii

CHAPTER ONE : INTRODUCTION ................................................................ 1

1.1 RESEARCH BACKGROUND .................................................................... 1

1.2 PROBLEM STATEMENT .......................................................................... 5

1.3 RATIONALE OF THE STUDY ................................................................. 5

1.4 RESEARCH OBJECTIVES ....................................................................... 6

1.4.1 Primary Objectives ........................................................................... 6

1.4.2 Secondary Objectives ....................................................................... 6

CHAPTER TWO : LITERATURE REVIEW .................................................... 7

2.1 PRINCIPLES OF ANTIRETROVIRAL THERAPYc ..................................... 7

2.2 NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) ........................................................................... 9

2.3 TIME TO INITIATE ANTIRETROVIRAL TREATMENT .............................. 10

2.4 EFFECTIVENESS AND SAFETY OF TDF + 3TC (OR FTC) REGIMEN COMPARED TO OTHER NRTIS COMBINATIONS ....................... 12

2.5 COST EFFECTIVENESS STUDIES OF REGIMEN CONTAINING TDF + 3TC/FTC ................................................................. 17

2.6 COMPARISON BETWEEN 3TC AND FTC ............................................ 19